tbuckley/cabot-search huggingface dataset:
1451P Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Authors: R. Bach Mora, P. Rocha, L. Masfarre Pinto, N. Navarro Gorro, A. Rossell, S. Gonzalez, X. Villanova, M. Giner, I. Sánchez, M.A. Galindo Campos, R. Del Rey-Vergara, A. Iñañez, A. Taus Garcia, L. Moliner, M. Hardy-Werbin, S. Clave, B. Bellosillo Paricio, A. Rovira, J. Perera-Bel, E. Arriola
Journal: Annals of Oncology (2023)
1443P Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Authors: M. Gogishvili, T. Melkadze, A. Baramidze, T. Makharadze, X. He, G. Gullo, P. Rietschel, R.G.W. Quek
Journal: Annals of Oncology (2023)
1454P Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Authors: S. Grisanti, M. Ravanelli, E. Fassi, P. Ciolli, A. Monti, P. Scolari, M. Mandruzzato, S. Bianchi, G. Carola, A. Baggi, A. Esposito, M. Vezzoli, S. Calza, D. Farina, A. Berruti
Journal: Annals of Oncology (2023)
1438P Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
Authors: T. Makharadze, M. Gogishvili, T. Melkadze, A. Baramidze, A. Sezer, S. Kilickap, M. Gumus, I. Bondarenko, K.D. Penkov, D. Giorgadze, M. Ozguroglu, E. Kalinka, D. McIntyre, M. Kaul, R.G.W. Quek, J-F. Pouliot, F. Seebach, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2023)
1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Authors: E. Felip, M.G. Krebs, E. Carcereny, K.B. Smeland, E. Arriola, C. Llacer Perez, J. Thompson, L. Paz-Ares, M. Domine Gomez, J.R. Olivares, N. Vinolas Segarra, M.R. García-Campelo, A.L.O. Ortega Granados, M. Chisamore, D. Micklem, N. McCracken, A. Rayford, C. Oliva, C. Gorcea-Carson, J. Spicer
Journal: Annals of Oncology (2023)
1455P Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Authors: M. Pérol, M. Sebastian, F. Barlesi, C. Schumann, D. Reynaud, D. Waldenberger, A. Lee, N. Varol, J.R. Penrod, F. Brellier
Journal: Annals of Oncology (2023)
1419P TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Authors: S. Hijazo-Pechero, A. Alay Badosa, N. Vilariño, J. Brenes Castro, L. Moliner, M-A. Mosteiro, N. Vidal, C. Muñoz-Pinedo, J. Bruna, E. Nadal
Journal: Annals of Oncology (2023)
1425P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Authors: R.M. El Sayed, W. Belkaid, C. Richard, X. Weng, R. Nassabein, R. Alameddine, F. Blanc-Durand, J. Roy, Y. Kim, I. Syed, N. Devost, D. Hui, G. Kenth, M. Florescu, B. Routy, M. Tehfe, G. Kasymjanova, J. Agulnik, N. Blais
Journal: Annals of Oncology (2023)
1426P Real-world data on next-generation sequencing using comprehensive genomic profiling assays for detecting driver oncogenes in advanced non-small cell lung cancer: Analysis with the National Database of Japan
Authors: I. Masaki, M. Iwasaku, R. Morita, T. Doi, T. Ishikawa, Y. Ogura, H. Kawachi, Y. Katayama, N. Nishioka, K. Morimoto, S. Tokuda, T. Yamada, T. Kohichi
Journal: Annals of Oncology (2023)
1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
Authors: F. Ghiringhelli, E. Felip, A. Zer, L. Greillier, A. Greystoke, N. Al-Sakaff, H-J. Helms, J.P. Pintoffl, S. Rahalkar, F.L. Lim, B.C. Cho
Journal: Annals of Oncology (2023)
1421P AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Authors: S-L. Lu, C. Duan, Y-C. Chang, C-H. Liang, P-L. Chiang, V. Lin, Y-S. Yang, A. Schayowitz, P. Selaru, K.D. Wilner, J-T. Lu
Journal: Annals of Oncology (2023)
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
Authors: J. M. O’Sullivan, J. Taylor, A. Gerds, S. Buckley, C. N. Harrison, S. Oh, A. F. List, K. Howard, H. Dreau, A. Hamblin, A. J. Mead
Journal: Leukemia (2023)
1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Authors: B.J. Solomon, A. Drilon, J.J. Lin, L. Bazhenova, K. Goto, J. De Langen, D-W. Kim, J. Wolf, C. Springfeld, S. Popat, D.W-T. Lim, C.S. Baik, A. Hervieu, V. Moreno Garcia, N. Yang, S. Thamake, F. Ades, D. Trone, B. Besse
Journal: Annals of Oncology (2023)
1351P Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Authors: D. Tao, H. Lei, J. Tan, D. Yang, Y. Jiang, W. Zhou, Y. Wang, Y. Wu
Journal: Annals of Oncology (2023)
1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Authors: L. Wu, J. Li, C. Xu, B. Biswas, K. Tang, H. Wang, Z. Liu, U. Batra, G.F. Ho, S.H.J. Low, Y. Lu, M. Zhao, L.M. Tho, J. Zhao, S. He, J. Huang, X. Tang, C.H. Wong, Y-L. Wu
Journal: Annals of Oncology (2023)
1338P Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Authors: B. Keam, H.A. Jung, T.M. Kim, H.R. Kim, C.G. Kim, H. Ahn, Y. Lee, Y.J. Kim, M. Kim, J. Youk, J-M. Sun, S-H. Lee, J.S. Ahn, D-W. Kim, M-J. Ahn
Journal: Annals of Oncology (2023)
1364P ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
Authors: J-J. Yang, J. Zhou, Y. Cheng, M. Li, Q. Zhao, Z-Y. Zhang, A. Zang, Y. Fan, Y. Zhou, J. Guo, Y. Zheng, Z. Wu, J. Sun, X. Xiang, X. Wang, Y-L. Wu
Journal: Annals of Oncology (2023)
1343P Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Authors: B.J. Krayim, W. Kian, N. Heching, A.A.R. Salhab, N. Asna, D. Kahala, L.C. Roisman, N. Peled
Journal: Annals of Oncology (2023)
1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Authors: R. Descourt, F. Guisier, M. Pérol, J. Cadranel, M. Duruisseaux, H. Doubre, S. Culine, C. Lamour, D. Moro-Sibilot, B. Mennecier, N. Martin, O. Bylicki, C. Chouaid, L. Greillier
Journal: Annals of Oncology (2023)
1344P A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Authors: J. Nieva, P.S. Karia, P. Okhuoya, M. Berktas, R.J-B. Salomonsen, L. Servidio, J. Chapaneri, K. De Silva, E. Martin, F. Griesinger
Journal: Annals of Oncology (2023)
1340P Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Authors: D. Zhang, X. Liu, F. Shen, D. Zhao, Y. Shi, H. Zhang, J. Liu, X. Gao, M. Chen, J. Zhao, W. Zhong, Y. Xu, M. Wang
Journal: Annals of Oncology (2023)
1341P Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Authors: P. Tian, L. Wu, C. Zhou, J. Tan, K. Wang, F. Luo, Y. Liu, Y. Guo, Y. Li, Z. Liu, Y. Gong, Y. Wang, W. Li
Journal: Annals of Oncology (2023)
1363P Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK+ Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
Authors: E. Vita, F. Monaca, J. Russo, A. Stefani, Q. Zhang, M. Di Salvatore, R. Trisolini, F. Lococo, A. Cancellieri, G. Tortora, E. Bria
Journal: Annals of Oncology (2023)
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Authors: S.M. Gadgeel, T.S.K. Mok, S. Peters, E. Nadal, J-Y. Han, J.A. Alatorre Alexander, N. Leighl, V. Sriuranpong, M. Pérol, G.D. Castro, F. de Marinis, D.S.W. Tan, S. Paul, Z.J. Assaf, M. MacLennan, T.O. Lohmann, M. Slade, M.S. Mathisen, V. Bhagawati-Prasad, R. Dziadziuszko
Journal: Annals of Oncology (2023)
1374P Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Authors: M. Glaser, S. Braegelmann, A. Rasokat, L. Nogova, C. Wömpner, J. Schmitz, E. Bitter, I. Terjung, A. Eisert, R.N. Fischer, F. John, S. Michels, R. Riedel, L.V. Ruge, H. Scharpenseel, U. Siebolts, S. Merkelbach-Bruse, R. Büttner, J. Wolf, M. Scheffler
Journal: Annals of Oncology (2023)
1375P Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Authors: F. Opdam, J. Heymach, G. Ruiter, M. Barve, H. Tu, Y-L. Wu, L. Schroeter, B. Sadrolhefazi, J. Serra, K. Yoh, N. Yamamoto
Journal: Annals of Oncology (2023)
1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Authors: J. Feng, K. Hueniken, Z. Fan, E. Faour, L. Corke, N. Leighl, G. Liu, P. Bradbury, A. Sacher, L. Eng, T. Stockley, M-S. Tsao, F.A. Shepherd
Journal: Annals of Oncology (2023)
1362P Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Authors: C. Aggarwal, A. Barakat, X. Tong, A. Krueger, B. Hupf, R. Fram, S. Vincent
Journal: Annals of Oncology (2023)
1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Authors: M. Brambilla, D. Lorenzini, M. Occhipinti, S. Manglaviti, T. Beninato, L. Mazzeo, L. Agnelli, R. Leporati, C. Zanella, A.G. Leone, G. Fotia, A. Prelaj, G. Lo Russo, I. Grande, E. Tamborini, F. Perrone, M. Ganzinelli, G. Pruneri, F.G.M. De Braud, C. Proto
Journal: Annals of Oncology (2023)
1366P Association between the adverse events and serum concentrations of lorlatinib in patients with advanced ALK-positive lung cancer
Authors: Y. Shimoda, T. Yoshida, R.A. Makihara, M. Torasawa, A. Tateishi, Y. Matsumoto, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Journal: Annals of Oncology (2023)
1345P Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Authors: M.R. Junttila, R. Warne, C. Repellin, L. Sambucetti, J. Chang, S. Kim, H.Y. Kim, D.G. Shin, D.H. Park, R. Patel, E. Chow Maneval, P.S. Multani, A. Daemen, L. Friedman
Journal: Annals of Oncology (2023)
1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Authors: E. Nadal, T.M. Kim, V. Guarneri, P.J. Voon, B.K. Lim, M. Wislez, C. Huang, C.K. Liam, J. Mazieres, L.M. Tho, H. Hayashi, N. Nguyen, P.L. Chia, F. de Marinis, S. Brutlach, S. Adrian, B. Ellers-Lenz, K. Berghoff, N. Karachaliou, Y-L. Wu
Journal: Annals of Oncology (2023)
1335P Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Authors: S. Puri, S. Patel, K. Kerrigan, A. Chalmers, S. George, P. Hammon, E. Loertscher, H. Lee, K. Boucher, W. Akerley
Journal: Annals of Oncology (2023)
1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Authors: M. Li, K. Mok, L.L. Chan, K.W.C. Lee, H.H.F. Loong, K.C. Lam, F. Mok, Y.M. Lau, O. Chen, J. Ng, B. Lam, A. Chen, W. Wong, T.S.K. Mok
Journal: Annals of Oncology (2023)
1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)
Authors: G. Liu, Q. Zhou, B.J. Solomon, H. Le, A. Reisman, D. Thomaidou, F. Toffalorio, J. Mazieres
Journal: Annals of Oncology (2023)
1347P Peripheral osimertinib (osi) plasma trough concentration (Cmin,SS) as surrogate parameter for development and progression of brain metastasis (BM) in patients (pts) with EGFR+ advanced non-small cell lung cancer (aNSCLC)
Authors: J.L. Gulikers, M.G.D. Veerman, M. Jebbink, P. Kruithof, C.M.J. Steendam, R. Boosman, R.H. Mathijssen, V. Tjan-Heijnen, A. Driessen, S. Dursun, E.F. Smit, A-M.C. Dingemans, R. van Geel, S. Croes, L. Hendriks
Journal: Annals of Oncology (2023)
1350P Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Authors: T. Tozuka, R. Noro, H. Mizutani, F. Kurimoto, T. Hakozaki, K. Hisakane, T. Naito, S. Takahashi, N. Taniuchi, C. Yajima, Y. Hosomi, T. Hirose, Y. Minegishi, T. Okano, K. Kamio, T. Yamaguchi, M. Seike
Journal: Annals of Oncology (2023)
1346P Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Authors: X. Li, X. Zheng, J. An, Y. Hua, X. Ding, H. Shi, W. Xu, Y. Li, L. Zhou
Journal: Annals of Oncology (2023)
1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Authors: Y-G. Lee, J.S. Ahn, M-J. Ahn, J.H. Kang, R.A. Soo, T. Reungwetwattana, J.C-H. Yang, I. Cicin, D-W. Kim, B. Zaric, H. Go, K.C. Jahng, S. Kim, Y. Lim, K.H. Lee, B.C. Cho
Journal: Annals of Oncology (2023)
1367P Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453
Authors: B.J. Sikkema, S.J. Baart, M.S. Paats, E.F. Smit, A.M. Schols, R.H. Mathijssen, E.F. van Rossum, A-M.C. Dingemans
Journal: Annals of Oncology (2023)
1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Authors: M.G. Denis, G. Herbreteau, C. Sagan, S. Charpentier, A. Vallée, J. Cadranel, C. Audigier Valette, P. Tomasini, P. Masson, E. Pons-Tostivint, H. Curcio, N. Girard, A. Cortot, O. Molinier, I. Monnet, M. Marcq, T. Urban, D. Moro-Sibilot, H. Lena, J. Bennouna
Journal: Annals of Oncology (2023)
1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Authors: M.H. Hong, A.I. Spira, K.H. Lee, E.K. Cho, J-Y. Han, B.Y. Shim, J-S. Lee, S.C-H. Kao, S-W. Kim, A. Khattak, M. Patel, R. Xu, J. Wang, E. Ariazi, A. Daemen, E. Chow Maneval, P.S. Multani, R. Patel, M-J. Ahn
Journal: Annals of Oncology (2023)
1368P LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Authors: C. Aggarwal, Q. Xu, S. Ng, R. Kamalakar, S.A. Crawford, S. Beruti, A. Myftiu, M.B. Beasley
Journal: Annals of Oncology (2023)
1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Authors: M. Pérol, N. Yang, C-M. Choi, Y. Ohe, S. Sugawara, N. Yanagitani, G. Liu, F.G.M. De Braud, J. Nieva, M. Nagasaka, L. Bazhenova, C. Zhou, E. Felip, X. Zhang, S. Li, N.A. Pennell
Journal: Annals of Oncology (2023)
1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
Authors: H.H.F. Loong, G. Daniele, T-Y. Yang, T.A. Leal, K. Goto, Y. Shinno, K. Nishino, T. Sakamoto, E. Felip, J.C. Ruffinelli, N. Gallot, Z. Wang, C. Chen, B. Brennan, S-F. Pu, M. Kornacker, P. Grassi, X. Le, D.S.W. Tan, B-C. Goh
Journal: Annals of Oncology (2023)
1480P Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Authors: J. Saal, T. Bald, M. Eckstein, D.J. Ralser, P. Brossart, J. Ellinger, M. Hölzel, N. Klümper
Journal: Annals of Oncology (2023)
1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
Authors: C. Molto, A.P. Restrepo, A.J. Templeton, A. Tibau, A. Mittal, F.T. Tamimi, D. Malon Gimenez, E. Amir
Journal: Annals of Oncology (2023)
1645P STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Authors: H.J. Mahadevia, U. Majeed, J. Starr, J.C. Jones, D. Ahn, S. Wu, J. Andring, H. El Shawa, J. Xiu, G. Sledge, I. Astsaturov, S. Goel, P.A. Philip, M. Borad, T. Bekaii-Saab, H. Babiker
Journal: Annals of Oncology (2023)
1717P Management of patients during a digital healthcare record system transition: A phase I unit experience
Authors: L. Del Rosario, B. Rao Baikady, S. Rodney, S. Gurung, S. Hammond, F. Cortes, S. MohamedKhan, C. Livings, T. Clark, R. Daly, G. Silva Fortes, K. Horvath, P. Lamb, A. Little, J.S. de Bono, U. Banerji, A.R. Minchom, J.S. Lopez, A. Sharp, A. Paschalis
Journal: Annals of Oncology (2023)
1667P Clinical and molecular features of young onset pancreatic adenocarcinoma
Authors: M. Remond, A.A. Tarabay, A. Hollebecque, M. Gelli, A. Mouawia, I. Ben Ammar, E. Fernandez de Sevilla, S. Cosconea, L. Tselikas, R. Barbe, A.C. Fuerea, M.A. Bani, M. Deloger, B. Besse, T. Pudlarz, M. Valery, V. Boige, C. Smolenschi, M.P. Ducreux, A. Boileve
Journal: Annals of Oncology (2023)
1468P Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Authors: M. Reck, A.L.O. Ortega Granados, F. de Marinis, Q. Shen, S.H. Boklage, C. Dabrowski, L. Cho, O. Meyers
Journal: Annals of Oncology (2023)
1674P VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Authors: S. Batko, M. Vocka, B.M. Duchoňová, M. Liberko, P. Májková, T. Buchler, L.B. Petruzelka, B. Melichar, R. Soumarova, K. Hejduk
Journal: Annals of Oncology (2023)
1662P Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Authors: P. Santofimia, N. Fraunhoffer, X. Liu, I. Fernandez-Bessone, M. Pasca di Magliano, S. Audebert, L. Camoin, M. Modesti, G. Lomberk, R. Urrutia, P. Soubeyran, J.L. Neira, J.L. Iovanna
Journal: Annals of Oncology (2023)
1715P Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Authors: A. Rossi, G. Aimar, M. Audisio, M. Bungaro, A. Caglio, R. Di Liello, T. Gamba, P. Gargiulo, E. Ghisoni, P. Lombardi, L. Marandino, A. Mariniello, C. Paratore, M.L. Reale, F. Trastu, V. Tuninetti, F. Turco, A. Fabi, F. Perrone, M. Di Maio
Journal: Annals of Oncology (2023)
1678P A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Authors: Y. Wu, X. Dong, E. Li, Y. Fan, D. Dong, Y. Shi, M. Wang, N. Yang, F. Ou, J. Wang, Y. Yang
Journal: Annals of Oncology (2023)
1479P Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Authors: H. Arasanz, N. Castro Unanua, L. Teijeira Sanchez, I. Morilla Ruiz, M. Martínez Aguillo, I. Labiano, A.E. Huerta-Hernández, P. Piedra Roset, M. Alsina Maqueda, R. Vera
Journal: Annals of Oncology (2023)
1682P Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Authors: E.L. Alouani, None C. canivet, B. Bournet, J. Selves, L. Buscail, B. Napoleon, L. Palazzo, N. Flori, P. Guibert, A. Albucher, A-C. Brunac, C. Maulat, F-Z. Mokrane, S. Gourgou, L. Gauthier, R. Guimbaud, N. Fares
Journal: Annals of Oncology (2023)
1459P Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Authors: C. Zhou, A. Xiong, X. Li, Y. Fan, W. Zhuang, Q. Yu, T. Xu, M. Xu, Q. Liu, N. Wang, X. Yan
Journal: Annals of Oncology (2023)
1695MO Cancer care during armed conflict: Factors associated with adult patient transfer for treatment abroad during the war in Ukraine
Authors: I. Huivaniuk, D. Kizub, V.S. Kopetskyi, A. Dzhemiliev, A. Kacharian, V. Strilka, A. Beznosenko, N. Melnitchouk
Journal: Annals of Oncology (2023)
1481P Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Authors: J.M. Jurado García, M. Cobo Dols, A. Cantero, V. Gutierrez Calderon, P. Jiménez Gallego, E. Perez Ruiz, M.A. Berciano Guerrero, A. Montesa Pino, I. Ramos Garcia, A. Rueda Dominguez
Journal: Annals of Oncology (2023)
1677P Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Authors: D. Lavacchi, C. Winchler, E. Giommoni, I.A. Vascotto, S. Romano, F. Scolari, A. Taddei, S. Pillozzi, A. Galli, L. Antonuzzo
Journal: Annals of Oncology (2023)
1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
Authors: S. van Waalwijk van Doorn-Khosrovani, C. Reparon, S. Koole, A. Huisman, C. Louis, M. van Aart, W. Groenen, K. Grunberg, E. Schuuring, V.T.H.B.M. Smit, K. Monkhorst, H. Gelderblom, S. van der Flier
Journal: Annals of Oncology (2023)
1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group
Authors: A. Pellat, T. Grinda, A. Prelaj, P. Cresta, A. Valachis, I. Zerdes, D. Martins Branco, L. Provenzano, A. Spagnoletti, G. Nader Marta, B. Wilson, F. Montemurro, L. Castelo-Branco, G. Pentheroudakis, S. Delaloge, M. Koopman
Journal: Annals of Oncology (2023)
1488P Exploring efficacy and safety of immune checkpoint inhibitors (ICI) in extensive stage (ES)- small-cell lung cancer (SCLC) in specific populations: Real-world data from the Durvalumab Expanded Access program Regional European cohort (DEAR)
Authors: A. Zer, U. Janzic, S. Daher, M. Unk, M.T. Moskovitz, O. Merimskiy, P. Garrido, M. Lupes, D. Araújo, M. Wollner, H.G. Sorotsky, O. Rotem, D. Urban, I. Chmielewska, A.M.P. Barroso
Journal: Annals of Oncology (2023)
1490P Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Authors: M. Bozkurt, D. Gökhan, M. Teomete, C. Turam, L. Florin, A. Ostrowski, R. Segal, V. Manax
Journal: Annals of Oncology (2023)
1476P Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Authors: A. Piedra, S. Martinez Recio, A. Hernandez Gonzalez, M.T. Moran Bueno, E. Arriola, J. Recuero-Borau, M. Cobo Dols, P. Cordeiro González, J. Mosquera Martinez, M.R. García-Campelo, A. Calles Blanco, R.M. Alvarez, M. Zapata García, M.D. Isla Casado, A. Callejo Perez, P. Iranzo Gomez, A. Barba Joaquín, I.G. Sullivan, E. Felip, M. Majem
Journal: Annals of Oncology (2023)
1698MO E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening
Authors: Q. Wang, M.L. Hsu, C. Wen, A. Dowlati, Y. Zhang, C. Jiang, D. Bruno, Y. Li, L. Deng, L. Chiec, G. Dutcher, C.Y. Kong
Journal: Annals of Oncology (2023)